Purpose:
To analyze reticular pseudodrusen (RPD) as an independent risk factor for progression to late age-related macular degeneration (AMD), alongside traditional macular risk factors (soft drusen and pigmentary abnormalities) considered simultaneously.
Design:
Post hoc analysis of 2 clinical trial cohorts: Age-Related Eye Disease Study (AREDS) and AREDS2.
Participants:
Eyes with no late AMD at baseline in AREDS (6959 eyes, 3780 participants) and AREDS2 (3355 eyes, 2056 participants).
Methods:
Color fundus photographs (CFPs) from annual visits were graded for soft drusen, pigmentary abnormalities, and late AMD. Presence of RPD was from grading of fundus autofluorescence images (AREDS2) and deep learning grading of CFPs (AREDS). Proportional hazards regression analyses were performed, considering AREDS AMD severity scales (modified simplified severity scale [person] and 9-step scale [eye]) and RPD presence simultaneously.
Main Outcome Measures:
Progression to late AMD, geographic atrophy (GA), and neovascular AMD.
Results:
In AREDS, for late AMD analyses by person, in a model considering the simplified severity scale simultaneously, RPD presence was associated with a higher risk of progression: hazard ratio (HR), 2.15 (95% confidence interval [CI], 1.75-2.64). However, the risk associated with RPD presence differed at different severity scale levels: HR, 3.23 (95% CI, 1.60-6.51), HR, 3.81 (95% CI, 2.38-6.10), HR, 2.28 (95% CI, 1.59-3.27), and HR, 1.64 (95% CI, 1.20-2.24), at levels 0-1, 2, 3, and 4, respectively. Considering the 9-step scale (by eye), RPD presence was associated with higher risk: HR, 2.54 (95% CI, 2.07-3.13). The HRs were 5.11 (95% CI, 3.93-6.66) at levels 1-6 and 1.78 (95% CI, 1.43-2.22) at levels 7 and 8. In AREDS2, by person, RPD presence was not associated with higher risk: HR, 1.18 (95% CI, 0.90-1.56); by eye, it was HR, 1.57 (95% CI, 1.31-1.89). In both cohorts, RPD presence carried a higher risk for GA than neovascular AMD.
Conclusions:
Reticular pseudodrusen represent an important risk factor for progression to late AMD, particularly GA. However, the added risk varies markedly by severity level, with highly increased risk at lower/moderate levels and less increased risk at higher levels. Reticular pseudodrusen status should be included in updated AMD classification systems, risk calculators, and clinical trials.
Citing Articles
Antioxidants in Age-Related Macular Degeneration: Lights and Shadows.
Parmar U, Surico P, Mori T, Singh R, Cutrupi F, Premkishore P
Antioxidants (Basel). 2025; 14(2).
PMID: 40002339
PMC: 11852319.
DOI: 10.3390/antiox14020152.
Current advances in multimodal imaging in geographic atrophy secondary to age-related macular degeneration: A review.
Cohn A, Guymer R
Taiwan J Ophthalmol. 2025; 14(4):464-472.
PMID: 39803396
PMC: 11717336.
DOI: 10.4103/tjo.TJO-D-24-00065.
TEN-YEAR FOLLOW-UP OF FELLOW EYES IN PATIENTS WITH UNILATERAL NAIVE EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
Pozzo Giuffrida F, Nassisi M, de Sanctis L, Milella P, Malerba A, Mapelli C
Retina. 2024; 44(12):2049-2056.
PMID: 39172949
PMC: 11559965.
DOI: 10.1097/IAE.0000000000004251.
Extent and Topography of Subretinal Drusenoid Deposits Associate With Rod-Mediated Vision in Aging and AMD: ALSTAR2 Baseline.
Goerdt L, Amjad M, Swain T, McGwin G, Clark M, Owsley C
Invest Ophthalmol Vis Sci. 2024; 65(10):25.
PMID: 39163034
PMC: 11343004.
DOI: 10.1167/iovs.65.10.25.
Reticular Pseudodrusen: Impact of Their Presence and Extent on Local Rod Function in Age-Related Macular Degeneration.
Kumar H, Guymer R, Hodgson L, Hadoux X, Jannaud M, van Wijngaarden P
Ophthalmol Sci. 2024; 4(6):100551.
PMID: 39161750
PMC: 11331943.
DOI: 10.1016/j.xops.2024.100551.
Predict and Protect: Evaluating the Double-Layer Sign in Age-Related Macular Degeneration.
Sivaprasad S, Chandra S, Sadda S, Teo K, Thottarath S, de Cock E
Ophthalmol Ther. 2024; 13(10):2511-2541.
PMID: 39150604
PMC: 11408448.
DOI: 10.1007/s40123-024-01012-y.
Retro Mode Imaging for Detection and Quantification of Sub-RPE Drusen and Subretinal Drusenoid Deposits in Age-Related Macular Degeneration.
Sassmannshausen M, Sautbaeva L, von der Emde L, Vaisband M, Sloan K, Hasenauer J
J Clin Med. 2024; 13(14).
PMID: 39064170
PMC: 11278487.
DOI: 10.3390/jcm13144131.
Progressive Choriocapillaris Changes on Optical Coherence Tomography Angiography Correlate With Stage Progression in AMD.
Romano F, Ding X, Yuan M, Vingopoulos F, Garg I, Choi H
Invest Ophthalmol Vis Sci. 2024; 65(8):21.
PMID: 38990069
PMC: 11246100.
DOI: 10.1167/iovs.65.8.21.
Geographic atrophy: pathophysiology and current therapeutic strategies.
Rajanala K, Dotiwala F, Upadhyay A
Front Ophthalmol (Lausanne). 2024; 3:1327883.
PMID: 38983017
PMC: 11182118.
DOI: 10.3389/fopht.2023.1327883.
Aging of the eye: Lessons from cataracts and age-related macular degeneration.
Cvekl A, Vijg J
Ageing Res Rev. 2024; 99:102407.
PMID: 38977082
PMC: 11288402.
DOI: 10.1016/j.arr.2024.102407.
An Updated Simplified Severity Scale for Age-Related Macular Degeneration Incorporating Reticular Pseudodrusen: Age-Related Eye Disease Study Report Number 42.
Agron E, Domalpally A, Chen Q, Lu Z, Chew E, Keenan T
Ophthalmology. 2024; 131(10):1164-1174.
PMID: 38657840
PMC: 11416341.
DOI: 10.1016/j.ophtha.2024.04.011.
Advanced age-related macular degeneration and risk factors in eyes with pachydrusen.
Nam S, Noh H, Yoon J, Ham D
Sci Rep. 2024; 14(1):6132.
PMID: 38480762
PMC: 10937650.
DOI: 10.1038/s41598-024-56404-8.
Age-Related Macular Degeneration, a Mathematically Tractable Disease.
Curcio C, Kar D, Owsley C, Sloan K, Ach T
Invest Ophthalmol Vis Sci. 2024; 65(3):4.
PMID: 38466281
PMC: 10916886.
DOI: 10.1167/iovs.65.3.4.
Repeatability of Rod-Mediated Dark Adaptation Testing in Normal Aging and Early and Intermediate Age-Related Macular Degeneration.
Owsley C, Swain T, McGwin Jr G, Bernard M, Clark M, Curcio C
Curr Eye Res. 2024; 49(7):725-730.
PMID: 38439539
PMC: 11199118.
DOI: 10.1080/02713683.2024.2326077.
Spatial Analysis Reveals Vascular Changes in Retinal and Choroidal Vessel Perfusion in Intermediate AMD With Reticular Pseudodrusen.
Nam J, Nivison-Smith L, Trinh M
Invest Ophthalmol Vis Sci. 2024; 65(2):33.
PMID: 38386332
PMC: 10896234.
DOI: 10.1167/iovs.65.2.33.
Association between Subretinal Drusenoid Deposits and Age-Related Macular Degeneration in Multimodal Retinal Imaging.
Krytkowska E, Olejnik-Wojciechowska J, Grabowicz A, Safranow K, Machalinska A
J Clin Med. 2023; 12(24).
PMID: 38137797
PMC: 10744131.
DOI: 10.3390/jcm12247728.
Lipofuscin, Its Origin, Properties, and Contribution to Retinal Fluorescence as a Potential Biomarker of Oxidative Damage to the Retina.
Rozanowska M
Antioxidants (Basel). 2023; 12(12).
PMID: 38136230
PMC: 10740933.
DOI: 10.3390/antiox12122111.
Retinal Findings and Cardiovascular Risk: Prognostic Conditions, Novel Biomarkers, and Emerging Image Analysis Techniques.
Colcombe J, Mundae R, Kaiser A, Bijon J, Modi Y
J Pers Med. 2023; 13(11).
PMID: 38003879
PMC: 10672409.
DOI: 10.3390/jpm13111564.
Treating patients with geographic atrophy: are we there yet?.
Antonio-Aguirre B, Fernando Arevalo J
Int J Retina Vitreous. 2023; 9(1):72.
PMID: 37986170
PMC: 10658861.
DOI: 10.1186/s40942-023-00493-6.
Whole genome sequencing of 4,787 individuals identifies gene-based rare variants in age-related macular degeneration.
Kwong A, Zawistowski M, Fritsche L, Zhan X, Bragg-Gresham J, Branham K
Hum Mol Genet. 2023; 33(4):374-385.
PMID: 37934784
PMC: 10840384.
DOI: 10.1093/hmg/ddad189.